Recent Company News

• 12:15 PM ET May 09, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 11-May

• 05:17 PM ET May 07, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:30 PM ET May 08, 2025
  

  Prothena Corp. reports Q1 EPS ($1.12) vs FactSet ($0.97) [8 est, ($1.19)-(0.50)] ($7.10, 0.00)

• 08:58 AM ET May 08, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:30 AM ET May 08, 2025
  

  FDA discloses paragraph IV patent certifications for Fotivda, Erivedge, and Erleada

• 09:21 AM ET May 07, 2025
  

  FDA panel to meet May 20-21 to discuss four separate regulatory applications in oncology

• 06:08 AM ET May 07, 2025
  

  Quick Take - European biotech/pharma sector lower in sympathy move after FDA picks Vinay Prasad as CBER director

• 06:01 AM ET May 07, 2025
  

  NICE recommends Pfizer's Adcetris in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (intraday in Japan, pre-European open) ($22.88, 0.00)

• 01:13 AM ET May 06, 2025
  

  Roche introduces Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity (CHF 272.00, 0.00)